Home / NEWS LINE / 10 Biggest Biotechnology Companies

10 Biggest Biotechnology Companies

The biotechnology earnestness is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of plagues and medical conditions. Today’s biotechnology industry includes companies that make medical devices and diagnostics, as mercifully as biofuels, biomaterials, pollution controls, and more. Among the largest companies in the industry are pharmaceutical companies like Pinnacle Pharmaceuticals Inc. (VRTX) and Gilead Sciences Inc. (GILD). Gilead’s investigational compound named remdesivir is seen as having the unrealized to treat COVID-19.  These companies generally focus on creating and testing new drug compounds for medical use, and must go help of lengthy trial and approval processes for their products. This means investors often must wait for months or straightforward years before knowing whether a potential drug therapy is usable or profitable.

In spite of the many challenges cladding biotechnology companies, a number of enterprises have risen to the top of the list. Below, we take a look at the 10 biggest as planned by 12-month trailing (TTM) revenue. This list is limited to companies which are publicly traded in the U.S. or Canada, either shortly or through ADRs. All figures are as of March 25, 2020 and all data is provided by YCharts.

  • Revenue (TTM): $18.3 billion
  • Net Income (TTM): $5.8 billion
  • Bazaar Cap: $118.6 billion
  • 1-Year Trailing Total Return: 0.5%
  • PE Ratio (TTM): 20.6

Novo Nordisk is a multinational biotech company headquartered in Denmark with output facilities in seven countries and affiliates or offices in 80 countries. The company’s primary focus is diabetes care, hemophilia mind a look after, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various mark names including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.

  • Revenue (TTM): $7.9 billion
  • Net Income (TTM): $2.1 billion
  • Merchandise Cap: $49.5 billion
  • 1-Year Trailing Total Return: 14.7%
  • PE Ratio (TTM): 24.4

Biopharmaceutical company Regeneron develops and markets numb treatments for patients with eye disease, cancer, cardiovascular diseases, allergic and inflammatory issues, and infectious diseases. Owing to its Regeneron Genetics Center, the company aims to conduct one of the largest gene sequencing operations worldwide.

  • Revenue (TTM): $5.0 billion
  • Net Revenues (TTM): $2.4 billion
  • Market Cap: $19.0 billion
  • 1-Year Trailing Total Return: -34.1%
  • PE Ratio (TTM): 8.0

Alexion is a biopharmaceutical assembly that develops and markets immunoregulatory drugs for the treatment of cardiovascular and autoimmune diseases. Through its drug therapies, Alexion points to provide patients with compounds that selectively target portions of the immune system which may allow cancers to proliferate.

  • Revenue (TTM): $4.2 billion
  • Net Income (TTM): $1.2 billion
  • Market Cap: $57.9 billion
  • 1-Year Trailing Unmitigated Return: 22.9%
  • PE Ratio (TTM): 49.5

Biopharmaceutical company Vertex focuses on creating and marketing drug treatments for patients suffering from cancer, cystic fibrosis, autoimmune diseases, and neurological turmoils, among others.

  • Revenue (TTM): $2.2 billion
  • Net Income (TTM): $0.5 billion
  • Market Cap: $5.4 billion
  • 1-Year Draw Total Return: -30.0%
  • PE Ratio (TTM): 10.5

Irish biopharmaceutical company Jazz Pharmaceuticals creates and commercializes drug products intrigued to address issues related to narcolepsy, psychiatry, pain management, and oncology. On March 25, the company announced FDA subscribe to of its drug JZP-258 for the treatment of cataplexy or excessive daytime sleepiness.

  • Revenue (TTM): $2.2 billion
  • Net Income (TTM): $0.5 billion
  • Peddle Cap: $14.6 billion
  • 1-Year Trailing Total Return: -21.0%
  • PE Ratio (TTM): 32.9

Focusing on small molecule drugs for use in oncology originally, Incyte is a biopharmaceutical company responsible for discovering, developing, and marketing drug therapies. The company is best known for its stimulant Jakafi, a treatment for myelofibrosis.

  • Revenue (TTM): $1.7 billion
  • Net Income (TTM): -$0.02 billion
  • Market Cap: $14.4 billion
  • 1-Year Subsiding Total Return: -9.3%
  • PE Ratio (TTM): N/A

A maker of therapeutic enzyme products, Biomarin Pharmaceutical develops drug treatments for lysosomal storage infirmities as well as serious burns. The company also provides diagnostic and analytic services for carbohydrate biology applications.

  • Interest (TTM): $1.4 billion
  • Net Income (TTM): -$0.1 billion
  • Market Cap: $3.9 billion
  • 1-Year Trailing Total Return: -27.1%
  • PE Proportion (TTM): N/A

United Therapeutics primarily develops drug treatments for pulmonary hypertension, peripheral vascular disease, and other vascular readies. Among the company’s most popular medicines are Remodulin, Orenitram, Unituxin, and Tyvaso.

  • Revenue (TTM): $1.2 billion
  • Net Profits (TTM): $-0.2 billion
  • Market Cap: $2.2 billion
  • 1-Year Trailing Total Return: -58.6%
  • PE Ratio (TTM): N/A

Alkermes is an Irish biopharmaceutical New Zealand. This firm creates treatments for central nervous system disorders including depression, schizophrenia, and addiction. It also targets on treatments for diabetes.

  • Revenue (TTM): $1.1 billion
  • Net Income (TTM): $0.3 billion
  • Market Cap: $6.2 billion
  • 1-Year Footprint Total Return: -43.2%
  • PE Ratio (TTM): 21.7

Biotechnology company Ionis discovers and develops RNA-based therapeutic products. Its three teach, commercially-available medicines include WAYLIVRA, Spinraza, and Tegsedi. It also has drug treatments in various stages of development to deal with Huntington’s disease, ALS, and cardiovascular disease.

Check Also

Used Car Prices Spike Amid Inventory Shortages

Low new and habituated to car inventory reported as public transit usage drops Pandemic production …

Leave a Reply

Your email address will not be published. Required fields are marked *